证券代码：002044 证券简称：美年健康 公告编号：2025-030 美年大健康产业控股股份有限公司 2024 年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会无否决或修改提案的情况，无涉及变更前次股东大会决议的 情况。 2、本次股东大会审议的全部议案已对中小投资者（指除上市公司的董事、监 事、高级管理人员以及单独或者合计持有上市公司5%以上股份的股东以外的股东） 的表决单独计票。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开的时间 （1）现场会议召开时间：2025 年 5 月 14 日（星期三）下午 14:30 （2）网络投票时间为：2025 年 5 月 14 日（星期三）9:15-15:00 1）通过深圳证券交易所交易系统进行网络投票的具体时间为 2025 年 5 月 14 日 9:15-9:25，9:30-11:30 和 13:00-15:00； 2）通过互联网投票系统进行网络投票的具体时间为 2025 年 5 月 14 日 9:15- 15:00 的任意时间。 2、现场会议召开地点：上海市 ...

资金面上看，今日基因测序概念板块获主力资金净流入4.22亿元，其中，33股获主力资金净流入，10股 主力资金净流入超千万元，净流入资金居首的是贝瑞基因，今日主力资金净流入1.38亿元，净流入资金 居前的还有东方海洋、华大基因、美年健康等，主力资金分别净流入1.31亿元、1.26亿元、3326.88万 元。 截至5月13日收盘，基因测序概念上涨1.23%，位居概念板块涨幅第10，板块内，39股上涨，贝瑞基 因、东方海洋等涨停，华大基因、迪安诊断、华大智造等涨幅居前，分别上涨14.55%、8.27%、 6.89%。跌幅居前的有新芝生物、谱尼测试、茂莱光学等，分别下跌1.66%、1.62%、1.61%。 今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | 中韩自贸区 | 3.03 | 中船系 | -3.40 | | 航运概念 | 2.51 | 国产航母 | -2.37 | | 硅能源 | 2.30 | 军工信息化 | -2.16 | | 环氧丙烷 | 1.95 | 太赫兹 | -2.14 | | 阿尔茨海默概念 | 1 ...

5月13日，美年健康今日收盘5.72元，上涨6.72%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到76.28倍，创31天以来新低，总市值223.90亿元。 美年大健康产业控股股份有限公司的主营业务是健康体检服务。公司的主要产品是体检服务。 最新一期业绩显示，2025年一季报，公司实现营业收入17.54亿元，同比-2.62%；净利润-275338119.16 元，同比3.94%，销售毛利率24.04%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)37美年健康76.2879.332.94223.90亿行业平均 38.5745.023.42152.74亿行业中值38.1250.592.7749.62亿1润达医疗-321.94213.042.78117.77亿2何氏眼 科-135.34-117.781.6932.27亿3*ST生物-114.09-110.929.3722.01亿4普瑞眼科-70.31-63.163.0164.34亿5诚达 药业-67.48-115.611.5232.49亿6皓宸医疗-51.14-61.516.0723.18亿7国际医学-46.79-47.053.35119 ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [2]. Core Insights - The report highlights a significant rebound in the stock prices of leading US healthcare AI companies, with Tempus and Grail both experiencing a 65% increase over the past month. This sector is noted for its rapid implementation and growing investor interest [8][10]. - It suggests focusing on domestic companies that can mirror the growth of these US AI leaders, particularly those like RunDa Medical and YiMaiTong, which are positioned to leverage AI for substantial performance gains [10][12]. Summary by Sections 1. Focus on US AI Leaders and Domestic Opportunities - The report emphasizes the recent stock price rebounds of US healthcare AI leaders, with notable increases of 65% for Tempus and Grail, and suggests that AI in healthcare is one of the fastest-growing fields [8]. - It recommends monitoring domestic companies such as RunDa Medical and YiMaiTong for potential investment opportunities as they implement AI solutions [10][12]. 2. Weekly Market Review and Hotspot Tracking (May 6 - May 9, 2025) - The report notes that the Shenwan Pharmaceutical and Biotechnology Index rose by 1.01% during the week, underperforming the CSI 300 Index by 1.0%. Year-to-date, the index has increased by 1.19%, outperforming the CSI 300 by 3.44% [32]. - The top-performing stocks during this period included Changshan Pharmaceutical (up 23.59%) and Xiangxue Pharmaceutical (up 19.64%) [44]. 3. Company Highlights - RunDa Medical has established deep collaborations with Huawei to implement AI solutions across over 80 hospitals, enhancing its digital healthcare offerings [12][13]. - YiMaiTong, a leading online professional physician platform in China, has seen its registered physician count grow to over 4 million, with a compound annual growth rate (CAGR) of 24.9% in paid clicks from 2018 to 2024 [17][20]. 4. Monthly Investment Portfolio - The report lists a monthly investment portfolio that includes companies such as Kangfang Biotech, Zai Lab, and Titan Technologies, indicating a focus on firms with strong fundamentals and growth potential [5].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002044 证券简称：美年健康 公告编号：2025-028 美年大健康产业控股股份有限公司 3、会议召开的合法、合规性：本次股东大会的召集、召开及审议事项符合《中华人民共和国公司法》 《中华人民共和国证券法》《深圳证券交易所股票上市规则》等法律、行政法规及《公司章程》等规 定，提案内容明确并在法定期限内公告。 4、会议召开的日期、时间： （1）现场会议召开时间：2025年5月14日（星期三）下午14:30。 关于召开2024年度股东大会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 特别提示： 美年大健康产业控股股份有限公司（以下简称"公司"）2024年度股东大会现场会议的召开地点为上海市 静安区灵石路697号健康智谷9号楼三楼公司会议室，敬请投资者特别留意。 根据公司于2025年4月15日召开的第九届董事会第八次会议，定于2025年5月14日召开公司2024年度股东 大会，本次股东大会将采用股东现场记名投票与网络投票表决相结合的方式召开，《关于召开2024年度 股东大会的通知》（公告 ...

美年大健康产业控股股份有限公司 证券代码：002044 证券简称：美年健康 公告编号：2025-029 特此公告。 美年大健康产业控股股份有限公司 监 事 会 二〇二五年五月十日 关于监事会延期换届的提示性公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 美年大健康产业控股股份有限公司（以下简称"公司"）第八届监事会任期将 于 2025 年 5 月 16 日届满。鉴于新修订的《中华人民共和国公司法》（以下简称 "公司法"）、《上市公司章程指引》及《关于新<公司法>配套制度规则实施相关 过渡期安排》等要求，以及公司换届工作尚在筹备中，为确保公司相关工作的连 续性和稳定性，公司第八届监事会的换届选举工作将适当延期。 在换届工作完成前，公司第八届监事会全体成员将依照相关法律法规以及 《深圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》《公司章程》等有关规定继续履行监事的职责和 义务。本次监事会延期换届不会影响公司的正常运营，公司将尽快推进相关工作， 并及时履行相应的信息披露义务。 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 美年大健康产业控股股份有限公司（以下简称"公司"）2024 年度股东大会现 场会议的召开地点为上海市静安区灵石路 697 号健康智谷 9 号楼三楼公司会议 室，敬请投资者特别留意。 根据公司于 2025 年 4 月 15 日召开的第九届董事会第八次会议，定于 2025 年 5 月 14 日召开公司 2024 年度股东大会，本次股东大会将采用股东现场记名投 票与网络投票表决相结合的方式召开，《关于召开 2024 年度股东大会的通知》 （公告编号：2025-021）已于 2025 年 4 月 17 日披露在《中国证券报》、《上海 证券报》、《证券时报》、《证券日报》和巨潮资讯网（www.cninfo.com.cn）。 现就本次股东大会的有关事宜发布提示性公告如下： 证券代码：002044 证券简称：美年健康 公告编号：2025-028 美年大健康产业控股股份有限公司 关于召开 2024 年度股东大会的提示性公告 （2）网络投票时间：2025 年 5 月 14 日（星期三）9:15-15:00。 1 1）通 ...

Core Viewpoint - The China Securities Index for Healthcare Equipment and Services has shown a recent increase, reflecting a mixed performance over different time frames [1][2]. Group 1: Index Performance - The China Securities Index for Healthcare Equipment and Services rose by 0.39% to 13,367.74 points, with a trading volume of 14.635 billion yuan [1]. - Over the past month, the index has increased by 5.82%, while it has decreased by 2.05% over the last three months and by 2.72% year-to-date [1]. Group 2: Index Composition - The index is composed of listed companies in the healthcare sector, selected from the broader China Securities Index to reflect the overall performance of healthcare-related securities [1]. - The top ten weighted companies in the index include: Mindray Medical (9.57%), Aier Eye Hospital (8.34%), United Imaging (7.63%), Aimeike (3.55%), Huatai Medical (3.28%), Yuyue Medical (2.88%), New Industry (2.81%), Meinian Onehealth (2.35%), Lepu Medical (2.07%), and Jiuan Medical (2.03%) [1]. Group 3: Market Segmentation - The index's holdings are primarily listed on the Shenzhen Stock Exchange (60.66%) and the Shanghai Stock Exchange (39.34%) [1]. - In terms of industry composition, medical devices account for 34.34%, medical consumables for 27.26%, in vitro diagnostics for 21.50%, and medical services for 16.90% [2]. Group 4: Fund Tracking - Several public funds track the China Securities Index for Healthcare Equipment and Services, including Southern China Securities Index Healthcare Equipment and Services Link A, C, and I, Tianhong China Securities Index Healthcare Equipment and Services ETF, and others [2].

Core Insights - The release of the "Ciming Beijing 2024 Annual Health Checkup Big Data Blue Book" aims to provide dynamic observation for public health research and optimize disease screening paths for medical institutions [1][2] - Ciming Health has introduced three innovative health management products that integrate smart technology and customized service systems to enhance public health literacy [1][2] Group 1: Blue Book Overview - The data for the Blue Book is sourced from health checkup data of 1.1346 million individuals from 19 health checkup centers in Beijing, focusing on common diseases in six major health areas [2] - The analysis targets the "post-70s," "post-80s," and "post-90s" demographics, with an average age of 43, comprising 51.9% males and 48.1% females [2] Group 2: Product Innovations - The three innovative health management products include weight management, blood sugar management, and the upgraded "Magnetic Capsule Gastroscope System" robot [1][14] - The weight management product offers a comprehensive approach with eight service items, including lifestyle assessments and personalized weight loss plans [14][15] - The blood sugar management product targets high-risk groups and provides a series of services to help manage and reverse diabetes effectively [14][15] Group 3: Industry Impact and Future Directions - Ciming Health is recognized for its contributions to health management and is seen as a pioneer in integrating smart medical innovations and health big data applications [7][9] - The company aims to leverage technology and innovation to drive high-quality development and establish itself as a leading brand in health checkups and management in the capital region [12][18] - Future initiatives will focus on cancer early screening, chronic disease management, and mental health, with a commitment to integrating digital operations and AI technologies [18]

Group 1 - The core viewpoint of the news is that a comprehensive financial policy package has been introduced to support the stability of the market and expectations, particularly benefiting the elderly care sector [1][3] - The People's Bank of China has established a 500 billion yuan service consumption and elderly care relending tool to enhance financial support for key areas such as elderly care and service consumption [3] - The elderly care industry in China is projected to reach a scale of 9 trillion yuan in 2022, with expectations to exceed 12 trillion yuan by 2025, indicating a significant growth phase ahead [4][5] Group 2 - The elderly care concept stocks have shown strong performance, with multiple stocks such as Jinming Precision Machinery and Xinhua Jin experiencing significant price increases, some reaching the daily limit [2] - The new policy tool is an expansion and upgrade of the previous inclusive elderly care relending policy, which had a smaller quota of 40 billion yuan and was initially piloted [3] - The silver economy is expected to grow substantially, with projections indicating it could reach 30 trillion yuan by 2035, accounting for 10% of GDP, driven by various sectors including elderly services and health care [4]